Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 7/20 | 0.46 |
| ▸ | CDK1 | P06493 | 5/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 4/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 4/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106064 | 0.87 | CYP2C19 (0.48) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL4110794 | 0.86 | PDPK1 (0.43) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL4098291 | 0.86 | CYP2C19 (0.51) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL4104321 | 0.86 | CYP2C19 (0.43) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL14692980 | 0.85 | CYP2C9 (0.41) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL4106873 | 0.82 | CYP2C19 (0.47) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL13848717 | 0.75 | SCN9A (0.50) | NEK2KCNH2SCN5ASCN9AMEN1 | |
| SCHEMBL4106347 | 0.74 | CDK2 (0.58) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL4110978 | 0.74 | CYP2C9 (0.57) | NEK2CDK2CDK1CCNB1CCNB2 | |
| SCHEMBL11946985 | 0.74 | CDK2 (0.44) | CDK2CDK1CCNB1CCNB2CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372852-B2 | Purines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | Andrea Boesciences, Inc. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2220091-B1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC (US) | 2012-07-25 | — | — | EP | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207178-B2 | Fused pyrimidines as reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2009079412-A2 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES INC. (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277206-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | NEK2 2436/4885CDK2 212/4885CDK1 572/4885 |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | POLRMT, POLR1E, TYMP | NEK2 2436/4885CDK2 212/4885CDK1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.